At midday, under a clear sky, hundreds of anxious Johane Masowe Vadzidzi VaJesu Church members were milling around Mudzidzi Wimbo's homestead in Madziva's Mutumba village. BY Everson Mushava Members of the Vadzidzi church at Mhukuta's ... Zimbabwe Standard, 1 month ago
Novartis CDK4/6 Inhibitor LEE011 (Ribociclib) Receives FDA Breakthrough Therapy Designation As First-Line Treatment For HR+/HER2- Advanced Breast Cancer Designation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer ...BioSpace, 3 weeks ago Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer SPi World News, 4 weeks ago
Juno Therapeutics Inc. plunged by a record 27 percent after three patients died in a trial for its lead cancer therapy and U.S. regulators put the study on hold, raising questions about the risks and tradeoffs of a new and very aggressive approach ...Bloomberg, 1 month ago
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
/PRNewswire/ -- Novartis announced today that The New England Journal of Medicine (NEJM) published data for PKC412 (midostaurin) demonstrating an overall response rate, defined as a major or partial response, of 60% (95% confidence interval [CI], ...TickerTech.com, 2 months ago
on your WebpageAdd Widget >Get your members hooked!